Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. If you’re ...

Non-small cell lung cancer has been notoriously difficult to treat because of its aggressive nature and tendency to relapse, even after initial successful treatments. This resistance is often linked ...

Circulating tumor cells allow researchers to detect cancer early, provide an accurate prognosis, monitor progression, and ...

The FDA has granted priority review to the supplemental biologics license application (sBLA) of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the first-line treatment of patients with ...

(Yicai) Sept. 25 -- Shares of Hengrui Pharmaceuticals rose after the drugmaker granted a unit of Indian peer Glenmark ...